Sionna Therapeutics, Inc. Common Stock (SION) - Total Liabilities
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has total liabilities worth $19.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sionna Therapeutics, Inc. Common Stock cash flow conversion to assess how effectively this company generates cash.
Sionna Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Sionna Therapeutics, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Sionna Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Snowsky Salt Industry Group Co Ltd
SHG:600929
|
China | CN¥2.91 Billion |
|
Devyani International Limited
NSE:DEVYANI
|
India | Rs42.48 Billion |
|
Shriram Pistons & Rings Limited
NSE:SHRIPISTON
|
India | Rs12.80 Billion |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥692.94 Million |
|
Zhejiang CONBA Pharmaceutical Co Ltd
SHG:600572
|
China | CN¥2.97 Billion |
|
Dis-Chem Pharmacies
JSE:DCP
|
South Africa | ZAC13.72 Billion |
|
Medicover AB (publ)
ST:MCOV-B
|
Sweden | Skr20.09 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥1.55 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Sionna Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Sionna Therapeutics, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sionna Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.12 Million | -94.53% |
| 2024-12-31 | $349.46 Million | +109.48% |
| 2023-12-31 | $166.83 Million | +6.06% |
| 2022-12-31 | $157.29 Million | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more